iPS Cells for Modelling and Treatment of Human Diseases
The field of reprogramming somatic cells into induced pluripotent stem cells (iPSC) has moved very quickly, from bench to bedside in just eight years since its first discovery. The best example of this is the RIKEN clinical trial this year in Japan, which will use iPSC derived retinal pigmented epit...
I tiakina i:
| Hōputu: | Online |
|---|---|
| Reo: | Ingarihi |
| I whakaputaina: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Ngā marau: | |
| Urunga tuihono: | 19008 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
| _version_ | 1869523655265878016 |
|---|---|
| collection | Directory of Open Access Books |
| description | The field of reprogramming somatic cells into induced pluripotent stem cells (iPSC) has moved very quickly, from bench to bedside in just eight years since its first discovery. The best example of this is the RIKEN clinical trial this year in Japan, which will use iPSC derived retinal pigmented epithelial (RPE) cells to treat macular degeneration (MD). This is the first human disease to be tested for regeneration and repair by iPSC-derived cells and others will follow in the near future. Currently, there is an intense worldwide research effort to bring stem cell technology to the clinic for application to treat human diseases and pathologies. Human tissue diseases (including those of the lung, heart, brain, spinal cord, and muscles) drive organ bioengineering to the forefront of technology concerning cell replacement therapy. Given the critical mass of research and translational work being performed, iPSCs may very well be the cell type of choice for regenerative medicine in the future. Also, basic science questions, such as efficient differentiation protocols to the correct cell type for regenerating human tissues, the immune response of iPSC replacement therapy and genetic stability of iPSC-derived cells, are currently being investigated for future clinical applications. |
| format | Online |
| id | doab-20.500.12854ir-50671 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-506712024-03-31T13:09:55Z iPS Cells for Modelling and Treatment of Human Diseases R5-920 clinical application differentiation adult stem cell human disease immune response induced pluripotent stem cells genetic cell stability thema EDItEUR::M Medicine and Nursing The field of reprogramming somatic cells into induced pluripotent stem cells (iPSC) has moved very quickly, from bench to bedside in just eight years since its first discovery. The best example of this is the RIKEN clinical trial this year in Japan, which will use iPSC derived retinal pigmented epithelial (RPE) cells to treat macular degeneration (MD). This is the first human disease to be tested for regeneration and repair by iPSC-derived cells and others will follow in the near future. Currently, there is an intense worldwide research effort to bring stem cell technology to the clinic for application to treat human diseases and pathologies. Human tissue diseases (including those of the lung, heart, brain, spinal cord, and muscles) drive organ bioengineering to the forefront of technology concerning cell replacement therapy. Given the critical mass of research and translational work being performed, iPSCs may very well be the cell type of choice for regenerative medicine in the future. Also, basic science questions, such as efficient differentiation protocols to the correct cell type for regenerating human tissues, the immune response of iPSC replacement therapy and genetic stability of iPSC-derived cells, are currently being investigated for future clinical applications. 2021-02-11T16:41:19Z 2021-02-11T16:41:19Z 2016-05-09 15:30:07 2015 book 19008 9783038421221 9783038421214 https://directory.doabooks.org/handle/20.500.12854/50671 eng application/octet-stream Attribution 4.0 International http://www.amazon.com/Cells-Modelling-Treatment-Human-Diseases/dp/3038421227/ref=sr_1_1?s=books&ie=UTF8&qid=1462800478&sr=1-1&keywords=iPS+Cells+for+Modelling+and+Treatment+of+Human+Diseases+MDPI http://www.mdpi.com/books/pdfview/book/163 MDPI - Multidisciplinary Digital Publishing Institute 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783038421221 9783038421214 422 open access |
| spellingShingle | R5-920 clinical application differentiation adult stem cell human disease immune response induced pluripotent stem cells genetic cell stability thema EDItEUR::M Medicine and Nursing iPS Cells for Modelling and Treatment of Human Diseases |
| title | iPS Cells for Modelling and Treatment of Human Diseases |
| title_full | iPS Cells for Modelling and Treatment of Human Diseases |
| title_fullStr | iPS Cells for Modelling and Treatment of Human Diseases |
| title_full_unstemmed | iPS Cells for Modelling and Treatment of Human Diseases |
| title_short | iPS Cells for Modelling and Treatment of Human Diseases |
| title_sort | ips cells for modelling and treatment of human diseases |
| topic | R5-920 clinical application differentiation adult stem cell human disease immune response induced pluripotent stem cells genetic cell stability thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 clinical application differentiation adult stem cell human disease immune response induced pluripotent stem cells genetic cell stability thema EDItEUR::M Medicine and Nursing |
| url | 19008 |